NasdaqCM - Delayed Quote • USD
Corcept Therapeutics Incorporated (CORT)
At close: May 7 at 4:00 PM EDT
Pre-Market: 8:50 AM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 5 | 5 |
| Avg. Estimate | 0.23 | 0.24 | 0.96 | 1.29 |
| Low Estimate | 0.2 | 0.22 | 0.86 | 0.55 |
| High Estimate | 0.28 | 0.29 | 1.11 | 1.81 |
| Year Ago EPS | 0.25 | 0.28 | 0.94 | 0.96 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 5 | 5 |
| Avg. Estimate | 155.23M | 162.08M | 632.15M | 707.87M |
| Low Estimate | 152.4M | 158.6M | 620.6M | 635M |
| High Estimate | 158.31M | 165M | 640.83M | 824.1M |
| Year Ago Sales | 109.69M | 119.68M | 482.38M | 632.15M |
| Sales Growth (year/est) | 41.50% | 35.40% | 31.00% | 12.00% |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | 0.15 | 0.22 | 0.26 | 0.22 |
| EPS Actual | 0.25 | 0.28 | 0.28 | 0.25 |
| Difference | 0.1 | 0.06 | 0.02 | 0.03 |
| Surprise % | 66.70% | 27.30% | 7.70% | 13.60% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0.23 | 0.24 | 0.96 | 1.29 |
| 7 Days Ago | 0.25 | 0.27 | 1.02 | 1.28 |
| 30 Days Ago | 0.27 | 0.29 | 1.09 | 1.38 |
| 60 Days Ago | 0.27 | 0.29 | 1.09 | 1.38 |
| 90 Days Ago | 0.23 | 0.24 | 0.91 | 1.63 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 2 | 1 | 1 | -- |
| Up Last 30 Days | 2 | 2 | 2 | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 3 | 4 | 3 | 4 |
Growth Estimates
| CURRENCY IN USD | CORT | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -8.00% | -- | -- | 8.00% |
| Next Qtr. | -14.30% | -- | -- | 11.70% |
| Current Year | 2.10% | -- | -- | 5.40% |
| Next Year | 34.40% | -- | -- | 13.20% |
| Next 5 Years (per annum) | -41.40% | -- | -- | 11.06% |
| Past 5 Years (per annum) | 4.84% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | HC Wainwright & Co.: Buy to Buy | 5/2/2024 |
| Maintains | Truist Securities: Buy to Buy | 5/2/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 4/23/2024 |
| Maintains | Truist Securities: Buy to Buy | 2/16/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 1/2/2024 |
| Maintains | Canaccord Genuity: Buy to Buy | 12/13/2023 |
Related Tickers
KRYS Krystal Biotech, Inc.
161.76
+3.07%
RYTM Rhythm Pharmaceuticals, Inc.
39.35
-10.32%
APLS Apellis Pharmaceuticals, Inc.
43.90
-10.06%
EXEL Exelixis, Inc.
22.15
+1.14%
CGON CG Oncology, Inc.
33.95
-3.28%
BPMC Blueprint Medicines Corporation
108.55
+2.16%
SWTX SpringWorks Therapeutics, Inc.
45.75
-1.23%
JANX Janux Therapeutics, Inc.
61.50
-1.11%
KURA Kura Oncology, Inc.
21.07
+0.29%
EYPT EyePoint Pharmaceuticals, Inc.
11.87
+5.98%